89581-64-6

Basic information

• Product Name: Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate
• Synonyms: Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate;6-Chloro-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid Methyl ester;methyl 3-chloro-6-oxo-1H-pyridazine-5-carboxylate
• CAS NO: 89581-64-6
• Molecular Formula: C₆H₅ClN₂O₃
• Molecular Weight: 188.5685
• Mol File: 89581-64-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate(89581-64-6)
• EPA Substance Registry System: Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate(89581-64-6)

Safety Data

• Hazardous Substances Data: 89581-64-6(Hazardous Substances Data)

Usage

General Description

Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate is a chemical compound with the molecular formula C7H7ClN2O3. It is an organic ester with a 2,3-dihydropyridazine core structure and a chloro and carbonyl functional groups. methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also utilized as a reagent in organic chemical reactions, such as the formation of new carbon-carbon and carbon-nitrogen bonds. Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate can be potentially hazardous if not handled and stored properly, and caution should be exercised when working with this chemical.

Upstream product

• 67-56-1 methanol 
• 50681-26-0 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid 
• 286946-24-5 methyl 3,6-dichloropyridazine-4-carboxylate 
• 51149-08-7 3,6-dichloropyridazin-4-carboxylic acid 

Downstream Products

• 89640-80-2 C₆H₆N₂O₃ 
• 1204400-37-2 C₁₃H₉ClF₂N₂O₃ 
• 1204400-38-3 C₁₂H₇ClF₂N₂O₃ 
• 1345443-39-1 C₁₃H₁₀F₂N₂O₄ 

Relevant articles and documents

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure-activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Q1 and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.